Drug Profile
BPI 42
Alternative Names: XMP 200Latest Information Update: 28 Jun 1999
Price :
$50
*
At a glance
- Originator XOMA
- Class Eye disorder therapies
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 28 Jun 1999 Discontinued-Preclinical for Eye disorders in USA (Ophthalmic)
- 26 Feb 1997 New profile
- 26 Feb 1997 Preclinical development for Eye disorders in USA (Ophthalmic)